PV701

AXP000115.1 · Oncolytic virus

Platform
Newcastle disease virus (attenuated MK107 lineage)
Originator
Pro-Virus
Sponsor
Wellstat Biologics

Names

NameTypeSource
PV701preferred name, codecurator, ncit
Oncolytic Newcastle Disease Virus Strain PV701synonymncit

Virus

Role
Oncolytic
Family
Paramyxoviridae
Virus
Newcastle disease virus (NCBI Taxonomy 2560319)
Strain
PV701 (attenuated MK107 lineage)
Replication
replicating
Modifications
none (naturally attenuated, non-recombinant)
Route
intravenous
Source
evidence

Cross-references

NCI Thesaurus
C2799

Approvals

No regulatory approval recorded.

Clinical trials (2)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT00081211Intratumoral PV701 in Treating Patients With Advanced or Recurrent Unresectable Squamous Cell Carcinoma of the Head and NeckTerminatedPhase 12004-042004-0730Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
NCT00055705PV701 in Treating Patients With Advanced or Recurrent Peritoneal CancerCompletedPhase 12003-01Cancer

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 17289893An optimized clinical regimen for the oncolytic virus PV701.Clinical cancer research : an official journal of the American Association for Cancer Research2007name in title: PV701
PMID 16638865A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization.Clinical cancer research : an official journal of the American Association for Cancer Research2006name in title: PV701
PMID 11980996Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology2002name in title: PV701

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 17346102Oncolytic virus therapy--foreword.Current cancer drug targets2007name in abstract: PV701
PMID 17346107Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus.Current cancer drug targets2007name in title: PV701
PMID 15983551A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2005name in title: PV701
PMID 14571286Gateways to clinical trials.Methods and findings in experimental and clinical pharmacology2003name in abstract: PV701
PMID 14755888Overview of phase I studies of intravenous administration of PV701, an oncolytic virus.Current opinion in molecular therapeutics2003name in title: PV701

NIH grants

ProjectTitleOrganisationPIYearsLinked by
M01RR000040UPCC: TRIAL OF INTRAVENOUS PV701 IN PTS W SOLID TUMORSUNIVERSITY OF PENNSYLVANIASTERMAN, DANIEL1999–2002name in title: PV701

Notes

Naturally attenuated, non-recombinant mesogenic NDV. Developed by Pro-Virus, which became Wellstat Biologics. Discontinued; no active trials found.

How to cite

PV701 (AXP000115.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000115.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.